| Description | TTP-8307 is a potent replication of several rhino- and enteroviruses inhibitor. |
| In vitro | TTP-8307 inhibits the replication of coxsackievirus B3 (CVB3 Nancy) (EC50 : 1.2 μM) and the three poliovirus Sabin strains, as well as coxsackieviruses A16 and A21 (EC50 of 0.85 and 5.34 μM). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 39, 45, 63, and 85. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307[1]. TTP-8307 inhibits OSBP-dependent viruses encephalomyocarditis virus (EMCV) and HCV[2]. |
| molecular weight | 436.48 |
| Molecular formula | C27H21FN4O |
| CAS | 950225-08-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. De Palma AM, et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009 May;53(5):1850-7. 2. Albulescu L, et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017 Apr;140:37-44. |